Curasight strengthens radiopharmaceutical theranostic strategy

Curasight A/S (“Curasight”) recently announced the addition of a new Phase I/IIa trial to the Company’s clinical therapeutic strategy, further accelerating and expanding the potential of its uPAR theranostic platform. This trial is planned to include five select cancer indications, and it will apply Curasight’s uPAR theranostic platform approach, which combines diagnosis (uTRACE®) and therapy (uTREAT®).

The upcoming basket trial is designed to investigate the diagnostic and treatment platforms in brain cancer (Glioblastoma), neuroendocrine tumors (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer. By expanding the trial to include these five different cancer types, Curasight aims to take advantage of its theranostic platform’s ability to work across tumor types, as uPAR is expressed in the majority of all solid cancers.

Curasight plans to dose the first patients in the beginning of 2025, with expected first efficacy data available in the same year. The Company’s CEO, Ulrich Krasilnikoff, expressed optimism about the potential of the theranostic approach using radiopharmaceuticals to both diagnose and treat certain types of cancer, emphasizing potential therapeutic efficacy data by the year 2025.

The basket trial is part of Curasight’s broader strategy to lead in the field of theranostics within radiopharmaceuticals and diagnostics. Additionally, in light of the trial’s expansion and acceleration, the Company intends to launch a rights issue during the first quarter of 2024 to bolster its capital structure and secure funding for clinical activities.

In addition to the upcoming Phase I/IIa trial, Curasight also has an ongoing Phase II trial investigating uTRACE in prostate cancer as part of a partnership agreement with Curium Inc. The Partnership Agreement outlines Curasight’s responsibility for development until regulatory approval, with Curium responsible for manufacturing and commercialization. Under the terms of the deal, Curasight is entitled to receive up to mUSD 70 in development and commercial milestones, as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

As a company on the forefront of theranostics technology, Curasight has developed a novel and innovative theranostics platform for improved cancer diagnosis and treatment. This technology combines targeted radionuclide therapy to treat cancer and non-invasive PET imaging for diagnosing and monitoring, known as Theranostics (Therapy + Diagnostics = Theranostics). By targeting uPAR, Curasight’s theranostic solution is designed for more precise prediction of treatment location.

Curasight is committed to advancing medical innovations in oncology and remains confident in the potential of its uPAR theranostic platform to revolutionize cancer diagnosis and treatment. For more information about Curasight and its groundbreaking theranostic technology, please visit http://www.curasight.com.

Source link



Leave a Reply

Your email address will not be published. Required fields are marked *

Most Viewed

Featured Franchise Opportunity

Starz Program

Child Related Franchises, Education & Training Franchises, Fitness & Recreation Franchises

$10ˌ000 - $50ˌ000

Buffalo Wild Wings Go

Food & Beverage Franchises, Full Service Restaurant Franchises

$250ˌ000 - $500ˌ000